Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current readings: Window-of-opportunity trials for thoracic malignancies.

Seminars in thoracic and cardiovascular surgery - 1 Jan 2014

Tsao Anne S

Abstract excerpt

Recent major advances in metastatic non-small cell lung cancer have occurred with the identification of molecular biomarker targets and administration of novel agents with resulting improvement in clinical outcomes. In the early-stage setting, personalized therapy with novel agents and molecular profiling are being incorporated into neoadjuvant "window-of-opportunity" trials. These important studies enable...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant
Share to Clinical Trials as Topic
Share to Molecular Diagnostic Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoadjuvant Therapy

Share to Neoplasm Staging

Share to Patient Selection

Share to Precision Medicine

Share to Predictive Value of Tests

Source

Identifiers

PMID: 25837547
DOI: 10.1053/j.semtcvs.2014.12.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current readings: Window-of-opportunity trials for thoracic malignancies.PMID 25837547Read ↗

Targeted Therapy in Early Stage Non-small Cell Lung Cancer.Semantic proximity Read ↗

Perioperative targeted therapy for oncogene-driven NSCLC.Semantic proximity Read ↗

Current indications for surgery in patients with lung cancer after neoadjuvant targeted therapy: a systematic review.Semantic proximity Read ↗

Perioperative Therapy in Oncogene-Driven Non-Small Cell Lung Cancer: Current Strategies and Unanswered Questions.Semantic proximity Read ↗

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer.Semantic proximity Read ↗

Best Practices for the Multidisciplinary Care of Patients With Early-Stage Driver-Mutated Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study.Semantic proximity Read ↗

The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer.Semantic proximity Read ↗

Is It Time to Implement Adjuvant Targeted Therapy in EGFR-Mutant Non-Small-Cell Lung Cancer?Semantic proximity Read ↗

Biologic approaches to drug selection and targeted therapy: hype or clinical reality?Semantic proximity Read ↗

Neoadjuvant immunochemotherapy vs. neoadjuvant targeted therapy plus chemotherapy for EGFR-mutated non-small cell lung cancer: a retrospective study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.